Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC28A1 | O00337 | 1/20 | 0.32 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.32 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.32 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.32 |
| ▸ | DUT | P33316 | 3/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17807707 | 1.00 | SLC28A1 (0.32) | SLC28A1SLC28A2SLC29A1SLC28A3DUT | |
| SCHEMBL10238922 | 1.00 | SLC28A1 (0.32) | SLC28A1SLC28A2SLC29A1SLC28A3DUT | |
| SCHEMBL15782468 | 1.00 | SLC28A1 (0.32) | SLC28A1SLC28A2SLC29A1SLC28A3DUT | |
| SCHEMBL15765635 | 0.90 | SLC28A1 (0.31) | SLC28A1SLC28A2SLC29A1SLC28A3DUT | |
| SCHEMBL1591858 | 0.90 | SLC28A1 (0.31) | SLC28A1SLC28A2SLC29A1SLC28A3DUT | |
| SCHEMBL16647500 | 0.86 | SLC28A1 (0.32) | SLC28A1SLC28A2SLC29A1SLC28A3DUT | |
| SCHEMBL17191717 | 0.85 | SLC28A1 (0.34) | SLC28A1SLC28A2SLC29A1SLC28A3DUT | |
| SCHEMBL17191712 | 0.83 | MEN1 (0.32) | DUT | |
| SCHEMBL17029543 | 0.82 | — | — | |
| SCHEMBL14946358 | 0.82 | SLC28A1 (0.33) | SLC28A1SLC28A2SLC29A1SLC28A3DUT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 95 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250057867-A1 | NUCLEOSIDE PHOSPHORAMIDATES | GILEAD SCIENCES INC (US) | 2025-02-20 | — | — | US | disclosed |
| EP-3321275-B1 | CRYSTALLINE FORM OF SOFOSBUVIR | GILEAD SCIENCES INC (US) | 2022-07-13 | — | — | EP | disclosed |
| EP-3290428-B1 | TABLET COMPRISING CRYSTALLINE (S)-ISOPROPYL 2-(((S)-(((2R,3R,4R,5R)-5-(2,4-DIOXO-3,4-DIHYDROPYRIMIDIN-1 (2H)-YL)-4-FLUORO-3-HYDROXY-4-METHYLTETRAHYDROFURAN-2-YL)METHOXY)(PHENOXY)PHOSPHORYL)AMINO)PROPANOATE | GILEAD PHARMASSET LLC (US) | 2021-10-13 | — | — | EP | disclosed |
| US-20210106604-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | Janssen Pharmaceuticals, Inc. | 2021-04-15 | — | — | US | disclosed |
| US-10780105-B2 | Substituted nucleosides, nucleotides and analogs thereof | Janssen Biopharma, Inc. (US) | 2020-09-22 | — | — | US | disclosed |
| US-10370401-B2 | Substituted nucleosides, nucleotides and analogs thereof | Janssen Biopharma, Inc. (US) | 2019-08-06 | — | — | US | disclosed |
| US-10307439-B2 | Substituted nucleosides, nucleotides and analogs thereof | ALIOS BIOPHARMA, INC. (US) | 2019-06-04 | — | — | US | disclosed |
| US-20190054108-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | Janssen Pharmaceuticals, Inc. | 2019-02-21 | — | — | US | disclosed |
| EP-3321275-A1 | CRYSTALLINE FORM OF SOFOSBUVIR | Gilead Pharmasset LLC (US) | 2018-05-16 | — | — | EP | disclosed |
| EP-3290428-A1 | TABLET COMPRISING CRYSTALLINE (S)-ISOPROPYL 2-(((S)-(((2R,3R,4R,5R)-5-(2,4-DIOXO-3,4-DIHYDROPYRIMIDIN-1 (2H)-YL)-4-FLUORO-3-HYDROXY-4-METHYLTETRAHYDROFURAN-2-YL)METHOXY)(PHENOXY)PHOSPHORYL)AMINO)PROPANOATE | Gilead Pharmasset LLC (US) | 2018-03-07 | — | — | EP | disclosed |
| EP-2141172-B1 | Cyclopropyl polymerase inhibitors | JANSSEN PRODUCTS LP (US) | 2012-10-24 | — | — | EP | disclosed |
| EP-2432792-A1 | N- [ (2 ' R) -2 ' -DEOXY-2 ' -FLUORO-2 ' -METHYL-P-PHENYL-5 ' -URIDYLYL]-L-ALANINE 1-METHYLETHYL ESTER AND PROCESS FOR ITS PRODUCTION | Pharmasset, Inc. (US) | 2012-03-28 | — | — | EP | disclosed |
| US-20110251152-A1 | NUCLEOSIDE PHOSPHORAMIDATES | PHARMASSET, INC. (US) | 2011-10-13 | — | — | US | disclosed |
| US-20110251152-A1 | NUCLEOSIDE PHOSPHORAMIDATES | PHARMASSET, INC. (US) | 2011-10-13 | — | — | US | disclosed |
| US-20110092460-A1 | CYCLOPROPYL POLYMERASE INHIBITORS | CENTOCOR ORTHO BIOTECH PRODUCTS L.P. (US) | 2011-04-21 | — | — | US | disclosed |
| US-20110092460-A1 | CYCLOPROPYL POLYMERASE INHIBITORS | CENTOCOR ORTHO BIOTECH PRODUCTS L.P. (US) | 2011-04-21 | — | — | US | disclosed |
| WO-2010135569-A1 | N- [ (2 ' R) -2 ' -DEOXY-2 ' -FLUORO-2 ' -METHYL-P-PHENYL-5 ' -URIDYLYL] -L-ALANINE 1-METHYLETHYL ESTER AND PROCESS FOR ITS PRODUCTION | PHARMASSET, INC. (US) | 2010-11-25 | — | — | WO | disclosed |
| US-20100298257-A1 | NUCLEOSIDE PHOSPHORAMIDATES | PHARMASSET, INC. (US) | 2010-11-25 | — | — | US | disclosed |
| WO-2010000459-A1 | CYCLOPROPYL POLYMERASE INHIBITORS | CENTOCOR ORTHO BIOTECH PRODUCTS L.P. (US) | 2010-01-07 | — | — | WO | disclosed |
| EP-2141172-A1 | Cyclopropyl polymerase inhibitors | Ortho Biotech Products L.P. (US) | 2010-01-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10307439-B2 | Substituted nucleosides, nucleotides and analogs thereof | PNP, NT5C3B, TYMP | SLC28A1 32/4885SLC28A2 46/4885SLC29A1 14/4885 |
| US-20190054108-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | PNP, NUDT1, NT5C3B | SLC28A1 16/4885SLC28A2 20/4885SLC29A1 5/4885 |
| US-20250057867-A1 | NUCLEOSIDE PHOSPHORAMIDATES | PNP, RNGTT, NSUN2 | SLC28A1 59/4885SLC28A2 84/4885SLC29A1 36/4885 |
| US-20110092460-A1 | CYCLOPROPYL POLYMERASE INHIBITORS | POLR2E, POLR2H, CTR9 | SLC28A1 1521/4885SLC28A2 2086/4885SLC29A1 1219/4885 |
| US-20100298257-A1 | NUCLEOSIDE PHOSPHORAMIDATES | PNP, RNGTT, NSUN2 | SLC28A1 67/4885SLC28A2 88/4885SLC29A1 40/4885 |
| US-10370401-B2 | Substituted nucleosides, nucleotides and analogs thereof | PNP, NT5C3B, NUDT1 | SLC28A1 25/4885SLC28A2 31/4885SLC29A1 11/4885 |
| US-20110251152-A1 | NUCLEOSIDE PHOSPHORAMIDATES | PNP, RNGTT, NSUN2 | SLC28A1 59/4885SLC28A2 84/4885SLC29A1 36/4885 |
| US-10780105-B2 | Substituted nucleosides, nucleotides and analogs thereof | PNP, NUDT1, NT5C3B | SLC28A1 16/4885SLC28A2 20/4885SLC29A1 5/4885 |
| US-20210106604-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | PNP, NUDT1, NT5C3B | SLC28A1 16/4885SLC28A2 20/4885SLC29A1 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.